Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
MEK/ERK addiction in CNL/aCML.
Kesarwani M, Kincaid Z, Azam M. Kesarwani M, et al. Oncotarget. 2017 Nov 3;8(59):99215-99216. doi: 10.18632/oncotarget.22283. eCollection 2017 Nov 21. Oncotarget. 2017. PMID: 29245892 Free PMC article. No abstract available.
Overcoming AC220 resistance of FLT3-ITD by SAR302503.
Kesarwani M, Huber E, Azam M. Kesarwani M, et al. Blood Cancer J. 2013 Aug 30;3(8):e138. doi: 10.1038/bcj.2013.40. Blood Cancer J. 2013. PMID: 23995047 Free PMC article. No abstract available.
Enhanced MAPK signaling is essential for CSF3R-induced leukemia.
Rohrabaugh S, Kesarwani M, Kincaid Z, Huber E, Leddonne J, Siddiqui Z, Khalifa Y, Komurov K, Grimes HL, Azam M. Rohrabaugh S, et al. Among authors: kesarwani m. Leukemia. 2017 Aug;31(8):1770-1778. doi: 10.1038/leu.2016.376. Epub 2016 Dec 27. Leukemia. 2017. PMID: 28031554 Free PMC article.
Momelotinib is a highly potent inhibitor of FLT3-mutant AML.
Azhar M, Kincaid Z, Kesarwani M, Ahmed A, Wunderlich M, Latif T, Starczynowski D, Azam M. Azhar M, et al. Among authors: kesarwani m. Blood Adv. 2022 Feb 22;6(4):1186-1192. doi: 10.1182/bloodadvances.2021004611. Blood Adv. 2022. PMID: 34768286 Free PMC article.
Rational polypharmacological targeting of FLT3, JAK2, ABL, and ERK1 suppresses the adaptive resistance to FLT3 inhibitors in AML.
Azhar M, Kincaid Z, Kesarwani M, Menke J, Schwieterman J, Ansari S, Reaves A, Ahmed A, Shehzad R, Khan A, Syed N, Amir N, Wunderlich M, Latif T, Seibel W, Azam M. Azhar M, et al. Among authors: kesarwani m. Blood Adv. 2023 Apr 25;7(8):1460-1476. doi: 10.1182/bloodadvances.2022007486. Blood Adv. 2023. PMID: 36044389 Free PMC article.
The high NRF2 expression confers chemotherapy resistance partly through up-regulated DUSP1 in myelodysplastic syndromes.
Lin P, Ren Y, Yan X, Luo Y, Zhang H, Kesarwani M, Bu J, Zhan D, Zhou Y, Tang Y, Zhu S, Xu W, Zhou X, Mei C, Ma L, Ye L, Hu C, Azam M, Ding W, Jin J, Huang G, Tong H. Lin P, et al. Among authors: kesarwani m. Haematologica. 2019 Mar;104(3):485-496. doi: 10.3324/haematol.2018.197749. Epub 2018 Sep 27. Haematologica. 2019. PMID: 30262569 Free PMC article.
41 results